Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Parkinson’s disease (PD) is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal α-synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopamine...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-01-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2020.00004/full |
| _version_ | 1818617116503310336 |
|---|---|
| author | Alexandre Iarkov George E. Barreto George E. Barreto J. Alex Grizzell Valentina Echeverria Valentina Echeverria |
| author_facet | Alexandre Iarkov George E. Barreto George E. Barreto J. Alex Grizzell Valentina Echeverria Valentina Echeverria |
| author_sort | Alexandre Iarkov |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal α-synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopaminergic system, and the prevention of dopaminergic neuronal cell death in the midbrain. This review discusses the physiological mechanisms involved in PD as well as new and prospective therapies for the disease. The current data suggest that prevention or early treatment of PD may be the most effective therapeutic strategy. New advances in the understanding of the underlying mechanisms of PD predict the development of more personalized and integral therapies in the years to come. Thus, the development of more reliable biomarkers at asymptomatic stages of the disease, and the use of genetic profiling of patients will surely permit a more effective treatment of PD. |
| first_indexed | 2024-12-16T17:00:35Z |
| format | Article |
| id | doaj.art-e2145c71709f4bec988d93c78422d6be |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-12-16T17:00:35Z |
| publishDate | 2020-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-e2145c71709f4bec988d93c78422d6be2022-12-21T22:23:45ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652020-01-011210.3389/fnagi.2020.00004500814Strategies for the Treatment of Parkinson’s Disease: Beyond DopamineAlexandre Iarkov0George E. Barreto1George E. Barreto2J. Alex Grizzell3Valentina Echeverria4Valentina Echeverria5Laboratorio de Neurobiología, Facultad de Ciencias de la Salud, Universidad San Sebastián, Concepción, ChileDepartment of Biological Sciences, University of Limerick, Limerick, IrelandHealth Research Institute, University of Limerick, Limerick, IrelandDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado, Boulder, CO, United StatesLaboratorio de Neurobiología, Facultad de Ciencias de la Salud, Universidad San Sebastián, Concepción, ChileResearch & Development Service, Bay Pines VA Healthcare System, Bay Pines, FL, United StatesParkinson’s disease (PD) is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal α-synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopaminergic system, and the prevention of dopaminergic neuronal cell death in the midbrain. This review discusses the physiological mechanisms involved in PD as well as new and prospective therapies for the disease. The current data suggest that prevention or early treatment of PD may be the most effective therapeutic strategy. New advances in the understanding of the underlying mechanisms of PD predict the development of more personalized and integral therapies in the years to come. Thus, the development of more reliable biomarkers at asymptomatic stages of the disease, and the use of genetic profiling of patients will surely permit a more effective treatment of PD.https://www.frontiersin.org/article/10.3389/fnagi.2020.00004/fullgene therapypreventioncotininestem cellsprecision medicine |
| spellingShingle | Alexandre Iarkov George E. Barreto George E. Barreto J. Alex Grizzell Valentina Echeverria Valentina Echeverria Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine Frontiers in Aging Neuroscience gene therapy prevention cotinine stem cells precision medicine |
| title | Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine |
| title_full | Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine |
| title_fullStr | Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine |
| title_full_unstemmed | Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine |
| title_short | Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine |
| title_sort | strategies for the treatment of parkinson s disease beyond dopamine |
| topic | gene therapy prevention cotinine stem cells precision medicine |
| url | https://www.frontiersin.org/article/10.3389/fnagi.2020.00004/full |
| work_keys_str_mv | AT alexandreiarkov strategiesforthetreatmentofparkinsonsdiseasebeyonddopamine AT georgeebarreto strategiesforthetreatmentofparkinsonsdiseasebeyonddopamine AT georgeebarreto strategiesforthetreatmentofparkinsonsdiseasebeyonddopamine AT jalexgrizzell strategiesforthetreatmentofparkinsonsdiseasebeyonddopamine AT valentinaecheverria strategiesforthetreatmentofparkinsonsdiseasebeyonddopamine AT valentinaecheverria strategiesforthetreatmentofparkinsonsdiseasebeyonddopamine |